This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Thomas V. McCaffrey, MD, PhD; Frederic B. Meyer, MD; Virginia V. Michels, MD; David G. Piepgras, MD; Mitchell S. Marion, MD

Arch Otolaryngol Head Neck Surg. 1994;120(11):1211-1216.

Abstract
Objective
It has been known for some time that paragangliomas of the head and neck may be familial. Recent evidence suggests genomic imprinting is an important factor in the clinical development of these tumors. In genomic imprinting the imprintable gene is transmitted in a mendelian manner, but expression of the gene is determined by the sex of the transmitting parent. In the case of paragangliomas, the gene does not result in the development of tumors when maternally inherited. The purpose of this study was to determine if this hypothesis correctly predicted the inheritance pattern of familial paraganglioma in a large series of patients.

Setting
A retrospective review of case records of the Mayo Clinic, Rochester, Minn, a tertiary referral center, was performed for the years 1950 to 1992 to identify patients with familial paragangliomas of the head and neck.

Patients
A total of 38 patients with familial paragangliomas of the head and neck were identified in nine kindreds.

Results
Carotid body tumors were the most common paragangliomas of the head and neck (34 cases). Glomus jugulare or glomus vagale occurred in eight cases. In 16 (42%) of the patients there were multiple tumors. Surgical complications, primarily cranial nerve palsies, were more frequent for tumors larger than 5 cm in diameter.

Conclusions
An autosomal dominant inheritance pattern could be shown for paragangliomas of the head and neck that was consistent with genomic imprinting. It is recommended that all individuals in kindreds with paragangliomas be screened after the age of 16 years to detect early asymptomatic tumors.

(Arch Otolaryngol Head Neck Surg. 1994;120:1211-1216)

Author Affiliations
From the Departments of Otolaryngology (Dr McCaffrey), Neurologic Surgery (Drs Meyer and Piepgras), and Medical Genetics (Dr Michels), Mayo Clinic, Rochester, Minn; and the Division of Otolaryngology, Department of Surgery (Dr Marion), Mayo Clinic, Scottsdale, Ariz.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Patient With Malignant Paraganglioma Responding to the Multikinase Inhibitor Sunitinib Malate
Hahn et al.
JCO 2009;27:460-463.
FULL TEXT  

The prevalence of SDHB, SDHC, and SDHD mutations in patients with head and neck paraganglioma and association of mutations with clinical features
Badenhop et al.
J. Med. Genet. 2004;41:e99-e99.
FULL TEXT  

RESIDENT'S PAGE: PATHOLOGY
ASKIN and WESTRA
Arch Otolaryngol Head Neck Surg 1996;122:1012-1015.
ABSTRACT